Орлистат-Акрихин

Quick links

Choose a section

Quick links to important sections

Advertisements

Орлистат-Акрихин

Selected form

Advertisements
Advertisements

Overview of Орлистат-Акрихин

Property Description
Active ingredient Orlistat
Form Hard gelatin capsules
Pharmacological class Gastrointestinal lipase inhibitor
Common use Chronic weight management (obesity)
Origin Synthetic (derivative of tetrahydrolipostatin)

What Type of Medicine is Орлистат-Акрихин and What is Its Purpose?

Орлистат-Акрихин is a pharmaceutical preparation intended for the chronic weight management of individuals with excessive body weight or obesity. The active compound, Orlistat, is classified as a gastrointestinal lipase inhibitor, a distinct type of anti-obesity agent. This classification means the drug's general purpose is to assist in weight loss by limiting calorie absorption. Orlistat facilitates this by inhibiting the absorption of dietary fats in the digestive system. Its use is a recognized approach in managing weight-related health challenges.


What is the Composition and Origin of Orlistat?

The medicine is supplied as hard gelatin capsules for oral administration and is a single-ingredient product, featuring Orlistat as the sole active substance (INN). This active ingredient is a synthetic derivative of the naturally occurring compound lipstatin, chemically standardized as tetrahydrolipostatin. Орлистат-Акрихин is produced by the manufacturer Akrikhin and typically targets the Russian pharmaceutical market. Its composition as a capsule containing a dry powder formulation ensures the active compound is delivered directly to the gastrointestinal tract, where its local effect is required.


How Does Orlistat Achieve its Weight Management Effect?

Orlistat achieves its effect through a highly localized mechanism of action in the gut, acting as a potent inhibitor of gastric and pancreatic lipases. It prevents these enzymes from performing hydrolysis, which is the necessary process of breaking down triglycerides (dietary fats) into absorbable molecules. This action causes a portion of the fat consumed to remain undigested, leading to a reduction in absorbed calories. Orlistat works by inhibiting these enzymes in the lumen of the gastrointestinal tract to decrease systemic absorption of dietary fat, thereby creating a caloric deficit by directly preventing fat digestion.

Regulatory References

  1. Orlistat - StatPearls (NIH)
Advertisements

What side effects are possible with Орлистат-Акрихин?

Possible Side Effects and Safety Information

The official regulatory safety profile for Orlistat is characterized by frequent, localized gastrointestinal effects that directly result from its mechanism as a lipase inhibitor. These effects are generally mild and transient, with regulatory documents noting they tend to occur predominantly early in the course of treatment, typically within the first three months. The severity of these primary effects is associated with the fat content of the diet.


Frequency-Based Adverse Reactions

Adverse reactions are classified by frequency based on clinical trial data and post-marketing reports:

  • Very Common (ge 1/10): Oily spotting (from rectum), flatus with discharge, faecal urgency, fatty/oily stools, oily evacuation, increased defecation, abdominal discomfort/pain, and headache.
  • Common (ge 1/100 to < 1/10): Faecal incontinence, nausea, rectal pain, soft stools, liquid stools, upper respiratory infection, urinary tract infection, and anxiety.

Serious Adverse Reactions and Restrictions

Post-marketing surveillance has documented rare but clinically significant serious adverse reactions affecting multiple organ systems, the frequency of which is often classified as not known.

  • Hepatobiliary and Renal Systems: Reports include severe liver injury (such as hepatitis and hepatic failure) and oxalate nephropathy, which can potentially lead to renal failure. The risk of oxalate nephropathy is heightened in individuals with pre-existing chronic kidney disease.
  • Immune System: Serious hypersensitivity reactions, including anaphylaxis, have been documented.

This medicine is contraindicated in patients with chronic malabsorption syndrome and cholestasis. Furthermore, official labeling states it is contraindicated during pregnancy and breast-feeding. Orlistat may also impair the absorption of fat-soluble vitamins (A, D, E, K), and reduced efficacy has been reported for certain co-administered medications, including levothyroxine and some antiepileptics.

Advertisements

Overdose and Emergency Response

Overdose: What Official Information States

Official regulatory information addresses the possibility of overdose with orlistat based on clinical trials and post-marketing reports. The data indicate that orlistat has minimal systemic absorption, meaning high doses are not expected to cause severe, prolonged systemic toxicity.

Documented Overdose Presentations

  • Symptoms: Post-marketing reports of overdose cases have indicated either no adverse events or only adverse events that are similar to those reported with the recommended dose (primarily gastrointestinal effects).
  • High Dose Studies: Single doses of up to 800 mg and multiple doses of up to 400 mg three times a day for 15 days were administered without resulting in clinically significant adverse findings.
  • Reversibility: Any potential systemic effects are considered likely to be rapidly reversible due to the drug's low systemic absorption profile.

When and How to Seek Help

  • Required Emergency Action: Should a significant overdose of orlistat occur, it is officially recommended that the patient be observed for 24 hours by a medical professional.
  • Urgent Medical Attention: For management of a suspected drug overdose, patients or caregivers should immediately contact their regional poison control centre for guidance. If the person has collapsed, is having a seizure, or is struggling to breathe, call emergency medical services immediately.
Advertisements

Therapeutic Uses of Орлистат-Акрихин

Орлистат-Акрихин is relevant for symptomatic management in the context of a treatment strategy for patients managing the long-term condition of excessive body weight, specifically obesity (BMI ge 30 kg/m²) and overweight (BMI ge 27 kg/m²) when associated with established comorbidities. This therapy is commonly used for managing the core symptomatic domain of abnormal or excessive fat accumulation. The medication plays a role in managing the cluster of symptoms related to systemic imbalance, including high cholesterol levels and impaired glucose tolerance. Its primary indications include patients with obesity, those who are overweight with comorbidities, and individuals seeking long-term management of the risk of weight regain.

“This supportive use is relevant for easing the overall symptom burden in conditions marked by increased physiological stress.”

This supportive use is applied in scenarios where additional management of discomfort is required alongside a comprehensive plan of diet and exercise. Where weight loss is achieved, the treatment contributes to easing the overall symptom load and **may help patients cope more steadily with symptom fluctuations.


Quick Fact: Supportive Management for Excessive Body Weight The medication is commonly used for managing symptoms that interfere with daily comfort, providing support that helps ease the overall symptom burden associated with chronic weight management.

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Орлистат-Акрихин?

Eligibility for Orlistat (Орлистат-Акрихин) is strictly defined by regulatory guidelines, primarily based on the patient's initial body weight criteria and the absence of specific medical conditions. The medicine is officially indicated for Adults with a Body Mass Index (BMI) of ge 30 kg/m^2 (obesity), or a BMI of ge 27 kg/m^2 if they have associated weight-related risk factors such as hypertension or diabetes. The prescription formulation is also approved for adolescents aged 12 years and older.


Absolute Contraindications

Orlistat must not be used by individuals with the following officially documented conditions:

  • Chronic Malabsorption Syndrome
  • Cholestasis (a liver disorder where bile flow is impaired)
  • Pregnancy or Breastfeeding
  • Known Hypersensitivity to orlistat or any component of the formulation

Restrictions and Conditional Use

Caution and specific monitoring are required for populations with underlying conditions that may be affected by the drug's mechanism. Use is restricted in patients at risk for renal impairment (kidney stone history or hyperoxaluria) due to the risk of oxalate nephropathy. Patients taking Cyclosporine must administer the medications at least three hours apart.

Advertisements

What should I know about interactions with other medicines?

The official regulatory interaction profile for Орлистат-Акрихин (Orlistat) is defined by its localized action, which results in the reduced intestinal absorption of co-administered medicines and products.


Documented Interaction Patterns

Type of Interaction Description Constraint/Requirement
Reduced Drug Exposure Co-administration may decrease the plasma concentration of certain drugs, including ciclosporin and amiodarone. Requires more frequent monitoring of the co-administered drug’s levels.
Reduced Nutrient Absorption The inhibition of dietary fat absorption directly causes reduced absorption of fat-soluble vitamins (A, D, E, and K). Mandatory co-administration of a multivitamin supplement containing these vitamins.
Anticoagulant Risk Interaction with Vitamin K absorption may alter the effectiveness of warfarin and other oral anticoagulants. Requires closer monitoring of Prothrombin Time/INR.

Timing-Based Separation Rules

To mitigate the risk of reduced drug absorption, specific administration timing is officially mandated:

  • Levothyroxine must be administered at least four hours apart from the dose of Orlistat.
  • The required multivitamin supplement must be administered at least two hours before or after the dose of Orlistat, such as at bedtime.

These official statements structure how the product is to be used concurrently with other necessary medicines and supplements.

Advertisements

Mechanism of Action

Irreversible Inhibition of Gastrointestinal Lipases

The mechanism of Orlistat involves a highly localized peripheral action by functioning as an irreversible inhibitor of the main digestive enzymes, gastric and pancreatic lipases. It forms a covalent bond with the essential active site of these enzymes, leading to their irreversible inactivation before they can break down dietary fat.

Disruption of the Triglyceride Hydrolysis Cascade

The inactivation of these lipases directly halts the physiological process of triglyceride hydrolysis, preventing the necessary breakdown of long-chain dietary fats into absorbable monoacylglycerols and free fatty acids. This action disrupts the intestinal absorption pathway, resulting in a reduction in the systemic assimilation of fat-derived calories.

Mechanism Limitations: Substrate Specificity

The drug's mechanism is strictly defined by its substrate specificity and only targets enzymes involved in fat digestion; it does not interfere with the absorption of carbohydrates or proteins. Furthermore, this mechanism has no physiological effect on the mobilization or catabolism of stored body fat, limiting its function to the reduction of caloric assimilation from consumed fat.

Advertisements

Dosage and Administration Information

How to Use Орлистат-Акрихин: Administration Guidelines

The usage of Orlistat is structured by specific dietary and temporal requirements to ensure its proper, localized action within the gastrointestinal tract. The medicine is intended for oral use as a hard capsule, swallowed with water.

Standard Dosage and Frequency

The standard regimen for adults and adolescents aged 12 years and older is 120 milligrams (mg) per dose, taken three times a day (TID). The total daily maximum is restricted to 360 mg. Dosing must occur in conjunction with the consumption of meals: one capsule is administered immediately before, during, or up to one hour after each of the three main meals of the day.

Contextual Use and Procedural Requirements

Proper administration is contingent upon the meal's composition. Orlistat is intended for use alongside a nutritionally balanced, reduced-calorie diet where approximately 30% of total calories are derived from fat. The dose is omitted if a meal is skipped or contains no fat, as the drug's action is dependent on the presence of dietary triglycerides.

A key procedural constraint involves vitamin intake: a multivitamin supplement containing fat-soluble vitamins (A, D, E, K) is required as part of the overall regimen. To prevent the drug from interfering with vitamin absorption, this supplement is taken at least two hours before or after the Orlistat dose, or optimally, at bedtime. The treatment is intended for long-term chronic management, with clinical assessment for continuation being part of the management plan if specific weight loss thresholds are not met after 12 weeks.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research on the Combination of Drug A and Drug B

Research evaluated whether the combination of Drug A and Drug B was associated with changes in symptom scores. The body of evidence includes several Phase 2 and Phase 3 randomized controlled trials (RCTs), alongside observational studies.

The primary focus of this research examined outcomes in individuals with the target condition.

  • One study reported that the combination was evaluated for its effect on the time to symptom onset and the duration of observed effect on pain scores in participants with severe symptoms.
  • Observations from trials also covered the average change in severity scores over a 12-week period.

Study Findings and Context

The studies reported findings from mild-to-moderate cases, and some research examined outcomes over a long-term period.

A large Phase 3 trial compared the combination's outcomes to monotherapy with Drug A alone. The trial observed the extent of change in patient condition during the first week of treatment.


Research on Administration and Study Demographics

The studies examined whether co-administration with food affected the outcome measures. Research included exclusion criteria related to pre-existing heart conditions. Details on the full safety profile and study demographics are available in the clinical trial publications. It is not yet clear whether the long-term use of this combination is associated with different outcomes compared to short-term use.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Орлистат-Акрихин (FAQ)


Q: Are there any serious side effects associated with Орлистат-Акрихин?

Regulatory documents state that rare but clinically significant serious adverse reactions have been reported via post-marketing surveillance. These include severe liver injury, such as hepatic failure, and oxalate nephropathy, which can potentially affect the kidneys. Serious allergic reactions (hypersensitivity) have also been documented in the safety profile.


Q: Is it normal to have a change in bowel movements while using this?

Regulatory documents describe changes in bowel movements as very common outcomes in clinical data, which are understood to be related to the drug’s mechanism of blocking fat digestion. These changes can include fatty/oily stools, increased defecation, and faecal urgency. The official safety profile indicates these effects are generally mild and tend to occur predominantly early in the course of treatment.


Q: Does the drug have any known long-term risks?

The medicine is indicated for chronic management, and post-marketing surveillance reports on rare serious events like liver injury. Studies show that levels of fat-soluble vitamins typically remained within the normal range for participants who used a multivitamin supplement as recommended in the regimen, addressing a key nutritional concern for long-term use.


Q: Does taking Орлистат-Акрихин affect liver function?

Official information mentions reports of severe liver injury (hepatitis or hepatic failure) as a serious adverse reaction documented in the safety profile. Additionally, the medicine is officially contraindicated, meaning its use is restricted, in individuals who have the liver disorder known as cholestasis.


Q: Can people with thyroid problems use Орлистат-Акрихин?

The official product information notes a specific interaction with the thyroid hormone replacement medicine Levothyroxine. To help avoid the risk of reduced Levothyroxine absorption, official administration timing suggests the medications be administered at least four hours apart.


Q: Is Орлистат-Акрихин the same as other orlistat medications?

Орлистат-Акрихин uses the active substance Orlistat. Official regulatory guidance indicates that generic medicines, such as different brands of Orlistat, contain the same active ingredient and are approved to perform similarly to other formulations.


Q: How quickly does Орлистат-Акрихин start working?

The physiological effect of the medicine begins relatively quickly. Based on clinical measurements of fat content in the stool, the drug’s intended action can be seen as soon as 24 to 48 hours after a patient takes the first dose.


Q: Can Орлистат-Акрихин cause stomach issues?

Official documents describe that a number of common gastrointestinal side effects are associated with the drug's action. These effects often include abdominal discomfort or pain and nausea, and they are noted as very frequent in the regulatory safety profile.


Q: Are there any vitamins I shouldn't take with Орлистат-Акрихин?

The drug is known to reduce the absorption of fat-soluble vitamins (A, D, E, and K). This does not mean these vitamins must be avoided, but the official regimen includes a multivitamin supplement, which regulatory guidance suggests is administered at least two hours before or after the Orlistat dose to help ensure proper absorption.


Q: What happens if I miss a dose of Орлистат-Акрихин?

Official administration guidelines provide instruction for this situation. The dose of the drug should be omitted (skipped) if a meal is missed entirely or if the meal contains no fat.


Q: How does Орлистат-Акрихин interact with blood thinners?

The drug may interfere with the absorption of Vitamin K, which can affect the action of oral anticoagulants (blood thinners) like warfarin. Regulatory requirements specify that patients taking these medications may require closer monitoring of their blood clotting levels (Prothrombin Time/INR).


Q: What happens if I stop taking Орлистат-Акрихин suddenly?

The physical effects of the drug cease relatively quickly after treatment is stopped. Studies indicate that the amount of unabsorbed fat in the stool typically returns to the pre-treatment level within 48 to 72 hours.


Q: Can teenagers use Орлистат-Акрихин?

The official eligibility criteria confirms that the prescription formulation is approved for use in adults and in adolescents who are 12 years of age and older.


Q: Why does the packaging mention fat-soluble vitamins?

The product information mentions these vitamins because the drug's mechanism is to prevent the digestion and subsequent absorption of dietary fat. Since fat is necessary for the body to absorb fat-soluble vitamins (A, D, E, K), their absorption may be reduced by the drug's action.


Q: Is there a maximum duration for using Орлистат-Акрихин?

While the drug is intended for chronic weight management, regulatory guidance indicates that patients are to be assessed for effectiveness after 12 weeks of use. This assessment may lead to discontinuation if a specific weight loss threshold has not been reached.


Q: Can a person with high blood pressure use this drug?

The official criteria for use includes individuals who have a Body Mass Index (BMI) of ge 27 kg/m^2 and who also have associated weight-related risk factors. Hypertension, or high blood pressure, is one of the risk factors explicitly mentioned that qualifies a patient for use.


Q: What is the difference between Orlistat and Xenical?

Orlistat is the active substance, which is the universally recognized generic name of the medicine. Xenical is the brand name used for a common prescription-strength formulation that contains the Orlistat active ingredient.


Q: Does the drug cause headaches or fatigue?

The regulatory safety data confirms both of these are potential adverse effects. Headache is listed as a Very Common adverse reaction, and fatigue is also listed as a Common side effect.


Q: Does the medication affect my appetite?

Official regulatory documents indicate that the drug's action is highly localized to the gut, where it blocks fat digestion. It does not operate on the central nervous system and is officially noted as not directly affecting a patient’s appetite control.


Q: Does using this drug affect my cholesterol levels?

Clinical trial results reported in official regulatory documents have shown that the use of the drug is associated with changes in certain metabolic markers. These changes include effects on Total Cholesterol and LDL-cholesterol levels.


Q: Why is a multivitamin sometimes mentioned alongside this treatment?

The need for a multivitamin supplement is mandated in the official instructions because the drug’s action reduces the body’s ability to absorb essential fat-soluble vitamins (A, D, E, K). Supplementation is required to help maintain adequate vitamin levels in the body.


Q: Is the drug preservative-free?

All components of the capsule, including the inactive ingredients that make up the shell and the powder, are specified in the product's official regulatory label. These ingredients are detailed in the description section of the drug information.


Q: What is the official shelf life of the product?

The drug's official regulatory instructions require that an Expiration Date (EXP) be printed directly on the medicine packaging. Patients must observe this date and should not use the product after it has expired.

Advertisements

How should Орлистат-Акрихин be stored and disposed of?

How to Store and Dispose of Орлистат-Акрихин?

Official regulatory documents define strict environmental and handling requirements to maintain the stability of Orlistat capsules.

Mandatory Storage Conditions

Requirement Official Instruction
Temperature Store at room temperature, typically not exceeding 25 C (or 30 C in some markets), and prevent freezing.
Protection Keep the medicine in its original packaging (blister or carton) to protect the contents from exposure to light and moisture.
Container Rule If supplied in a bottle, the container must be kept tightly closed, often due to the presence of a desiccant.
Child Safety The product must be kept out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Орлистат-Акрихин must be disposed of according to local or national pharmaceutical waste regulations. It is explicitly instructed that this medication should not be discarded by flushing it down a toilet or pouring it down a sink (wastewater).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Орлистат-Акрихин found in:

A-Z Index: